164 related articles for article (PubMed ID: 32873702)
1. p63 expression is associated with high histological grade, aberrant p53 expression and TP53 mutation in HER2-positive breast carcinoma.
Guo S; Wang Y; Rohr J; Shang L; Ma J
J Clin Pathol; 2021 Oct; 74(10):641-645. PubMed ID: 32873702
[TBL] [Abstract][Full Text] [Related]
2. The relationship between p63 and p53 expression in normal and neoplastic breast tissue.
Ribeiro-Silva A; Zambelli Ramalho LN; Britto Garcia S; Zucoloto S
Arch Pathol Lab Med; 2003 Mar; 127(3):336-40. PubMed ID: 12653579
[TBL] [Abstract][Full Text] [Related]
3. Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma.
Zhao D; Fu X; Rohr J; Wang Y; Li M; Zhang X; Qin J; Xu M; Li C; Sun G; Wang Z; Guo S
Pathol Res Pract; 2021 Dec; 228():153677. PubMed ID: 34775151
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of snail in metaplastic breast carcinoma.
Nassar A; Sookhan N; Santisteban M; Bryant SC; Boughey JC; Giorgadze T; Degnim A
Diagn Pathol; 2010 Nov; 5():76. PubMed ID: 21110878
[TBL] [Abstract][Full Text] [Related]
5. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma.
Koker MM; Kleer CG
Am J Surg Pathol; 2004 Nov; 28(11):1506-12. PubMed ID: 15489655
[TBL] [Abstract][Full Text] [Related]
6. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
[TBL] [Abstract][Full Text] [Related]
7. Does the correlation between EBNA-1 and p63 expression in breast carcinomas provide a clue to tumorigenesis in Epstein-Barr virus-related breast malignancies?
Ribeiro-Silva A; Ramalho LN; Garcia SB; Zucoloto S
Braz J Med Biol Res; 2004 Jan; 37(1):89-95. PubMed ID: 14689049
[TBL] [Abstract][Full Text] [Related]
8. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
[TBL] [Abstract][Full Text] [Related]
9. HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.
Guo W; Wang W; Zhu Y; Zhu X; Shi Z; Wang Y
Int J Clin Exp Pathol; 2015; 8(7):8008-17. PubMed ID: 26339367
[TBL] [Abstract][Full Text] [Related]
10. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
11. TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.
Chartier S; Brochard C; Martinat C; Coussy F; Feron JG; Kirova Y; Cottu P; Marchiò C; Vincent-Salomon A
Histopathology; 2023 Apr; 82(5):664-671. PubMed ID: 36527253
[TBL] [Abstract][Full Text] [Related]
12. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
13. p63 is useful in the diagnosis of mammary metaplastic carcinomas.
Tse GM; Tan PH; Chaiwun B; Putti TC; Lui PC; Tsang AK; Wong FC; Lo AW
Pathology; 2006 Feb; 38(1):16-20. PubMed ID: 16484002
[TBL] [Abstract][Full Text] [Related]
14. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.
Gudlaugsson E; Skaland I; Undersrud E; Janssen EA; Søiland H; Baak JP
Mod Pathol; 2011 Apr; 24(4):502-11. PubMed ID: 21317878
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
16. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
17. Metaplastic breast carcinomas and their relationship with basal-like phenotype.
Cakir A; Gönül II; Uluoğlu O
Turk Patoloji Derg; 2012; 28(2):134-41. PubMed ID: 22627631
[TBL] [Abstract][Full Text] [Related]
18. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
[TBL] [Abstract][Full Text] [Related]
19. High frequency of coexpression of maspin with p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of the lung.
Choy B; Findeis-Hosey JJ; Li F; McMahon LA; Yang Q; Xu H
Int J Clin Exp Pathol; 2013; 6(11):2542-7. PubMed ID: 24228118
[TBL] [Abstract][Full Text] [Related]
20. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]